215 related articles for article (PubMed ID: 15701432)
21. Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen.
Yang SL; Wang D; Wu WZ; Lin WH; Xu TZ; Cai JQ; Tan JM
Transpl Immunol; 2008 Jan; 18(3):281-5. PubMed ID: 18047938
[TBL] [Abstract][Full Text] [Related]
22. Basiliximab and rabbit anti-thymocyte globulin for prophylaxis of acute rejection after heart transplantation: a non-inferiority trial.
Carrier M; Leblanc MH; Perrault LP; White M; Doyle D; Beaudoin D; Guertin MC
J Heart Lung Transplant; 2007 Mar; 26(3):258-63. PubMed ID: 17346628
[TBL] [Abstract][Full Text] [Related]
23. Benefit of Neoral C2 monitoring in de novo cardiac transplant recipients receiving basiliximab induction.
Cantarovich M; Ross H; Arizón JM; Gómez MA; Straatman L; Orús J; Alonso-Pulpón L; Molina BD; Wang S; Lage E; Crespo MG; Manito N; Howlett J; Haddad H;
Transplantation; 2008 Apr; 85(7):992-9. PubMed ID: 18408580
[TBL] [Abstract][Full Text] [Related]
24. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial.
Neuhaus P; Clavien PA; Kittur D; Salizzoni M; Rimola A; Abeywickrama K; Ortmann E; Chodoff L; Hall M; Korn A; Nashan B;
Liver Transpl; 2002 Feb; 8(2):132-42. PubMed ID: 11862589
[TBL] [Abstract][Full Text] [Related]
25. Induction Immunosuppressive Therapy Use in Deceased Donor Kidney Transplantation: 11-Year Experience in Veracruz, Mexico.
Martinez-Mier G; Soto-Miranda E; Avila-Pardo SF; Budar-Fernandez LF; Mateu-Rivera LJ; Mendez-Lopez MT; Trujillo-Martinez MF; Uscanga-Montesano A; Avila Y Falfan D
Transplant Proc; 2016 Mar; 48(2):600-4. PubMed ID: 27110011
[TBL] [Abstract][Full Text] [Related]
26. Histological findings of early graft biopsies in old donor renal transplant patients receiving induction therapy.
Gavela E; Pallardó LM; Sancho A; Avilla A; Beltrán S; Roselló E; Pérez ML; García F
Transplant Proc; 2009; 41(6):2099-101. PubMed ID: 19715842
[TBL] [Abstract][Full Text] [Related]
27. Preserving renal function in liver transplant recipients with rabbit anti-thymocyte globulin and delayed initiation of calcineurin inhibitors.
Bajjoka I; Hsaiky L; Brown K; Abouljoud M
Liver Transpl; 2008 Jan; 14(1):66-72. PubMed ID: 18161842
[TBL] [Abstract][Full Text] [Related]
28. Basiliximab lowers the cyclosporine therapeutic threshold in the early post-kidney transplant period.
Balbontin F; Kiberd B; Fraser A; Kiberd M; Lawen J
Clin Transplant; 2005 Apr; 19(2):225-9. PubMed ID: 15740559
[TBL] [Abstract][Full Text] [Related]
29. A Single-Center Experience of the Optimal Initial Immunosuppressive Strategy for Preventing Early Acute Cellular Rejection in Orthotopic Heart Transplantation Associated With Renal Dysfunction.
Mundisugih J; Fernando H; Bergin P; Hare J; Kaye D; Leet A; McGiffin D; Taylor AJ
Prog Transplant; 2019 Dec; 29(4):327-334. PubMed ID: 31476958
[TBL] [Abstract][Full Text] [Related]
30. Mycophenolate mofetil in pediatric renal transplantation: non-induction vs. induction with basiliximab.
Ojogho O; Sahney S; Cutler D; Baron PW; Abdelhalim FM; James S; Zuppan C; Franco E; Concepcion W
Pediatr Transplant; 2005 Feb; 9(1):80-3. PubMed ID: 15667617
[TBL] [Abstract][Full Text] [Related]
31. A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation.
Mehra MR; Zucker MJ; Wagoner L; Michler R; Boehmer J; Kovarik J; Vasquez A
J Heart Lung Transplant; 2005 Sep; 24(9):1297-304. PubMed ID: 16143248
[TBL] [Abstract][Full Text] [Related]
32. Induction with basiliximab plus thymoglobulin is effective and safe in old-for-old renal transplantation: six-month results of a prospective clinical study.
Favi E; Gargiulo A; Spagnoletti G; Salerno MP; Silvestrini N; Valente I; Citterio F
Transplant Proc; 2010 May; 42(4):1114-7. PubMed ID: 20534237
[TBL] [Abstract][Full Text] [Related]
33. Cyclosporine-sparing effect of basiliximab in renal transplant recipients with mycophenolate mofetil.
Tojimbara T; Sato S; Koyama I; Nanmoku K; Sekijima M; Tonsyo M; Kai K; Kato Y; Urashima Y; Nakajima I; Fuchinoue S; Teraoka S
Transplant Proc; 2005 Mar; 37(2):895-8. PubMed ID: 15848568
[TBL] [Abstract][Full Text] [Related]
34. Induction with anti-thymocyte globulin in heart transplantation is associated with better long-term survival compared with basiliximab.
Ansari D; Lund LH; Stehlik J; Andersson B; Höglund P; Edwards L; Nilsson J
J Heart Lung Transplant; 2015 Oct; 34(10):1283-91. PubMed ID: 26087667
[TBL] [Abstract][Full Text] [Related]
35. Multicenter, randomized study of the effectiveness of basiliximab in avoiding addition of steroids to cyclosporine a monotherapy in renal transplant recipients.
Parrott NR; Hammad AQ; Watson CJ; Lodge JP; Andrews CD
Transplantation; 2005 Feb; 79(3):344-8. PubMed ID: 15699766
[TBL] [Abstract][Full Text] [Related]
36. Assessment of immunosuppression induction with basiliximab compared to antithymocyte-globulin in adult heart transplant patients.
Eberhardt TE; Kim DH; Nethersole S; Pearson GJ
Clin Transplant; 2024 Jun; 38(6):e15332. PubMed ID: 38804609
[TBL] [Abstract][Full Text] [Related]
37. Basiliximab induction and delayed calcineurin inhibitor initiation in liver transplant recipients with renal insufficiency.
Verna EC; Farrand ED; Elnaggar AS; Pichardo EM; Balducci A; Emond JC; Guarrera JV; Brown RS
Transplantation; 2011 Jun; 91(11):1254-60. PubMed ID: 21617588
[TBL] [Abstract][Full Text] [Related]
38. Effect of basiliximab on renal allograft rejection within 1 year after transplantation.
Lee BM; Oh CK; Jin SH; Kim JH; Kim SJ; Kim H; Shin GT
Transplant Proc; 2006 Sep; 38(7):2025-8. PubMed ID: 16979988
[TBL] [Abstract][Full Text] [Related]
39. Comparison of Basiliximab and Anti-Thymocyte Globulin as Induction Therapy in Pediatric Heart Transplantation: A Survival Analysis.
Ansari D; Höglund P; Andersson B; Nilsson J
J Am Heart Assoc; 2015 Dec; 5(1):. PubMed ID: 26722127
[TBL] [Abstract][Full Text] [Related]
40. Graft function, cardiovascular risk factors, and sex hormones in renal transplant recipients on an immunosuppressive regimen of everolimus, reduced dose of cyclosporine, and basiliximab.
Krämer BK; Neumayer HH; Stahl R; Pietrzyk M; Krüger B; Pfalzer B; Bourbigot B; Campbell S; Whelchel J; Eris J; Vitko S; Budde K;
Transplant Proc; 2005 Apr; 37(3):1601-4. PubMed ID: 15866684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
